ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Fadi Haddad(The University of Texas MD Anderson Cancer Center), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Diane Habib, Nitin Jain(The University of Texas MD Anderson Cancer Center)
Cited by 7
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
|American Journal of Hematology|2017|437